Adjuvant Trastuzumab Did Not Improve Outcomes for Patients With HER2-low Breast Cancer
Research led by Louis Fehrenbacher, MD, medical director of Kaiser Permanente Oncology Clinical Trials and an oncologist with the Kaiser Permanente Vallejo Medical Center, California found current guidelines guidelines for defining HER2-positive status remain valid.
The trial concluded that adding trastuzumab (Herceptin) to standard adjuvant chemotherapy did not improve invasive disease–free survival for patients with early-stage breast cancer.
Current guidelines classify a breast cancer as HER2 positive if immunohistochemistry testing shows it has high levels of HER2 protein, defined as IHC 3+, or in situ hybridization shows it has increased numbers of copies of the HER2 gene, defined as ISH positive. Adding one year of treatment with trastuzumab to standard adjuvant chemotherapy significantly reduces cancer recurrence and improves survival for patients with early-stage HER2-positive breast cancer.
About 15 percent of breast cancers are HER2 positive, but another 45 percent have low levels of HER2, and these patients are not currently treated with adjuvant trastuzumab. In some of the early trastuzumab clinical trials, there was a signal that patients with HER2-low breast cancer may benefit from the HER2-targeted therapeutic. We designed and conducted NSABP-B-47 to test in a large, rigorous clinical trial whether this was indeed the case.
Although the data show that adding trastuzumab to standard adjuvant chemotherapy did not improve outcomes for patients with early-stage HER2-low breast cancer, it was vital to have conducted the study so that patients with this form of the disease can unequivocally know that trastuzumab is not a beneficial treatment for them. Trastuzumab treatment can cause serious adverse effects, including cardiotoxicity, so it is important to know that current guidelines defining HER2-positive status are valid and ensure that no patients are under-or overtreated.
Fehrenbacher and colleagues enrolled 3,270 patients with early-stage breast cancer that was either IHC 1+, IHC 2+, and/or ISH negative in the trial. The patients were randomized 1:1 to standard adjuvant chemotherapy with or without a year of trastuzumab. After a median follow-up of 46.1 months, 264 patients had either recurrence of their original breast cancer, a diagnosis of a new breast cancer, a diagnosis of new cancer outside the breast, or had died. These 264 events triggered analysis of the primary endpoint of the trial, invasive disease–free survival.
Information taken from SABCS 2017 official Press Release.
Related news and insights
The digital ILC 2020 recently brought together over ten thousand scientific and medical professionals from a broad range of fields for three days of virtual sessions, ePosters and plenaries. If you couldn’t make it, catch-up with our highlights from this year’s congress.